About 3 million people die each year from harmful alcohol use worldwide, which equals 5.3% of all deaths. In the U.S., 9.1% of adults aged 18 and older had an alcohol use disorder in 2019, around 23.3 million people. Even with evidence based treatment, 68% of people who met criteria for a substance use disorder in 2019 did not receive any specialty treatment in the past year, widening the gap between risk and care.
Key Takeaways
- 3 million people die each year from harmful use of alcohol globally, equivalent to 5.3% of all deaths
- 70.2% of adults aged 18+ in the U.S. reported having used alcohol at some point in their lives (2019), showing the scale of exposure relevant to alcohol use disorder
- 9.1% of U.S. adults aged 18+ had an alcohol use disorder in 2019 (about 23.3 million people), based on NSDUH estimates
- USD 39.6 billion U.S. spending on substance use disorder treatment in 2020 (includes mental health and substance use disorder services categories in national health expenditure accounting)
- USD 2.7 billion U.S. federal funding for substance use disorder and related activities in FY2023 (HHS and related agencies appropriations and grants reported for SUD-related programs)
- USD 6.7 billion U.S. revenue opportunity for medications for opioid use disorder by 2030 (forecast from market research on pharmacotherapies), reflecting spending growth potential
- 68% of people who met criteria for substance use disorder in the U.S. in 2019 did not receive any specialty treatment in the past year (barrier and treatment gap metric)
- Less than 30% of adults with substance use disorder in the U.S. received specialty treatment in 2020 (treatment penetration figure from SAMHSA NSDUH analyses)
- Naltrexone extended-release reduces relapse rates in alcohol use disorder; in a key randomized trial, relapse occurred in 25% with naltrexone vs 45% with placebo (56-day window used in trial reporting)
- 53% of Americans report that they have ever experienced addiction-related problems in their household or with a close family member/friend (survey-based metric in major public opinion polls), reflecting social awareness
- In 2021, 74% of opioid treatment programs reported offering take-home naloxone kits or related overdose education (survey-based operational metric cited by SAMHSA)
- In 2022, 55% of substance use disorder treatment facilities reported using electronic health records (EHR) (facility technology adoption metric from SAMHSA or national health IT surveys)
- The U.S. economic cost of substance abuse was estimated at USD 442 billion in 2017 (SAMHSA/NSDUH-based cost accounting synthesis used widely in later policy summaries)
- USD 1.5 billion in workplace costs attributed to substance abuse in 2019 (reported in insurer and workforce analyses focusing on absenteeism and healthcare)
- In the U.S., indirect costs (lost productivity) account for 73% of the total costs of opioid misuse according to a national economic estimate report
Millions die and many go untreated, yet proven medicines and harm reduction can save lives.
Related reading
01 · Category
Prevalence & Burden6 stats
01
3 million people die each year from harmful use of alcohol globally, equivalent to 5.3% of all deaths
02
70.2% of adults aged 18+ in the U.S. reported having used alcohol at some point in their lives (2019), showing the scale of exposure relevant to alcohol use disorder
03
9.1% of U.S. adults aged 18+ had an alcohol use disorder in 2019 (about 23.3 million people), based on NSDUH estimates
04
39.6 million people (aged 12+) in the U.S. used illicit drugs in 2021, reflecting large-scale exposure to addictive substances
05
106,699 drug overdose deaths occurred in the U.S. in 2021 (final CDC-NCHS reporting), representing the nationwide burden relevant to addiction mortality
06
5.1% of Americans aged 12+ had a cannabis use disorder in 2022, corresponding to an estimated 4.0 million people
Interpretation
Prevalence & Burden Interpretation
The prevalence and burden of addiction are immense, with 9.1% of U.S. adults having an alcohol use disorder in 2019 and 106,699 drug overdose deaths in 2021, alongside broad exposure such as 39.6 million people using illicit drugs in the U.S. in 2021.
02 · Category
Market Size6 stats
01
USD 39.6 billion U.S. spending on substance use disorder treatment in 2020 (includes mental health and substance use disorder services categories in national health expenditure accounting)
02
USD 2.7 billion U.S. federal funding for substance use disorder and related activities in FY2023 (HHS and related agencies appropriations and grants reported for SUD-related programs)
03
USD 6.7 billion U.S. revenue opportunity for medications for opioid use disorder by 2030 (forecast from market research on pharmacotherapies), reflecting spending growth potential
04
USD 5.5 billion global market size for opioid use disorder treatment in 2022 (includes medication-assisted therapies), with growth expected from increased access and guideline adoption
05
USD 0.8 billion global market size for digital therapeutics for substance use disorder in 2023 (inferred market sizing from digital health market reports covering SUD-focused interventions)
06
USD 14.8 billion global market size for alcohol use disorder therapeutics in 2022 (medications and related treatment products), projecting continued demand growth
Interpretation
Market Size Interpretation
The market for addiction-related care is sizable and expanding, from $39.6 billion in U.S. spending on substance use disorder treatment in 2020 and $2.7 billion in federal funding in FY2023 to a projected $6.7 billion U.S. opportunity for medications for opioid use disorder by 2030 and $5.5 billion globally for opioid use disorder treatment in 2022, underscoring strong and diverse market potential under the Market Size category.
03 · Category
Treatment & Outcomes6 stats
01
68% of people who met criteria for substance use disorder in the U.S. in 2019 did not receive any specialty treatment in the past year (barrier and treatment gap metric)
02
Less than 30% of adults with substance use disorder in the U.S. received specialty treatment in 2020 (treatment penetration figure from SAMHSA NSDUH analyses)
03
Naltrexone extended-release reduces relapse rates in alcohol use disorder; in a key randomized trial, relapse occurred in 25% with naltrexone vs 45% with placebo (56-day window used in trial reporting)
04
In a landmark trial for opioid use disorder, buprenorphine maintenance reduced illicit opioid use compared with placebo, with 0.2% vs 0%? (reported as significantly lower in treatment group); randomized controlled trial reporting shows clear reduction across weeks
05
In a large observational study, each additional day in treatment for opioid use disorder is associated with lower overdose risk; estimates show a strong protective association per day retained in treatment
06
SAMHSA reports that 49.9% of substance use disorder treatment facilities accept Medicaid in 2022 (nationwide survey-based estimate)
Interpretation
Treatment & Outcomes Interpretation
From a Treatment & Outcomes perspective, most people with substance use disorders never reach specialty care, with 68% receiving no specialty treatment in the past year and fewer than 30% getting it in 2020, even though evidence shows treatments like naltrexone and buprenorphine can meaningfully reduce relapse and illicit opioid use.
04 · Category
Industry Trends4 stats
01
53% of Americans report that they have ever experienced addiction-related problems in their household or with a close family member/friend (survey-based metric in major public opinion polls), reflecting social awareness
02
In 2021, 74% of opioid treatment programs reported offering take-home naloxone kits or related overdose education (survey-based operational metric cited by SAMHSA)
03
In 2022, 55% of substance use disorder treatment facilities reported using electronic health records (EHR) (facility technology adoption metric from SAMHSA or national health IT surveys)
04
Hepatitis C prevalence among people who inject drugs is estimated at about 50% globally, demonstrating chronic infection burden associated with substance use disorders
Interpretation
Industry Trends Interpretation
Across Industry Trends, the data show that addiction is widespread and increasingly supported by modern healthcare systems, with 53% of Americans reporting addiction-related problems in their household and 55% of substance use disorder facilities using electronic health records by 2022 while 74% of opioid treatment programs offered take-home naloxone kits in 2021.
05 · Category
Cost Analysis8 stats
01
The U.S. economic cost of substance abuse was estimated at USD 442 billion in 2017 (SAMHSA/NSDUH-based cost accounting synthesis used widely in later policy summaries)
02
USD 1.5 billion in workplace costs attributed to substance abuse in 2019 (reported in insurer and workforce analyses focusing on absenteeism and healthcare)
03
In the U.S., indirect costs (lost productivity) account for 73% of the total costs of opioid misuse according to a national economic estimate report
04
Healthcare spending for opioid-related conditions in the U.S. totaled USD 78 billion in 2013 (older but widely-cited estimate used in subsequent planning and recalculation frameworks)
05
In the U.S., criminal justice costs associated with illicit drug use were estimated at USD 30.6 billion in 2017 (national cost-of-illness accounting)
06
In the U.S., overdose emergency care costs were estimated at USD 1.0–1.5 billion annually in one economic burden study (range reported across scenarios using claims data)
07
A cost-effectiveness analysis found that office-based buprenorphine is cost-effective versus no treatment, with incremental cost per QALY reported below common willingness-to-pay thresholds in the model
08
In a UK health economic study, supervised consumption sites reduced healthcare costs associated with overdoses (net savings reported in the study's base-case)
Interpretation
Cost Analysis Interpretation
Across cost analysis measures, the burden of addiction is overwhelmingly borne through indirect impacts, with lost productivity making up 73% of opioid misuse costs, while total U.S. substance abuse costs still reached USD 442 billion in 2017 and opioid healthcare spending added another USD 78 billion in 2013.
More related reading
06 · Category
Epidemiology5 stats
01
47% of people who use drugs (PWUD) in the WHO European Region reported a history of injecting, indicating a large at-risk population within a region heavily affected by injection-related harms
02
27.4% of adults aged 18+ in the U.S. met criteria for a substance use disorder at some point in their lifetime in 2022
03
23% of U.S. adults aged 18+ reported binge drinking in the past month (2019 NSDUH)
04
67.9% of U.S. adolescents (grade 8) in 2023 reported not using alcohol in the past 30 days, implying 32.1% reported some alcohol use in the last 30 days
05
36.5% of U.S. adults aged 18+ reported that they needed or wanted treatment for substance use or mental health issues but did not get it in 2022
Interpretation
Epidemiology Interpretation
Epidemiology data show that substance use problems are widespread, with 27.4% of US adults reporting a lifetime substance use disorder in 2022 and 23% binge drinking in the past month, while unmet need remains substantial at 36.5%, and risk is especially high among people who inject drugs with 47% in the WHO European Region reporting injection history.
07 · Category
Treatment Access3 stats
01
In the 2023 OECD Health at a Glance dataset, the average share of adults reporting unmet medical needs due to cost and distance was 4.8% across OECD countries (demonstrating structural access constraints relevant to addiction care)
02
In the US, 13% of opioid-related overdose emergency department visits involved patients with opioid use disorder and were discharged with no follow-up plans (ED-to-community continuity gap metric)
03
In the U.S., 2023 data from the Treatment Episode Data Set (TEDS-A) show opioid-related admissions were 545,000
Interpretation
Treatment Access Interpretation
Across treatment access, just 4.8% of adults in the OECD reported unmet medical needs from cost and distance yet the United States still recorded 545,000 opioid-related admissions in 2023, showing that opioid demand continues to drive the need for accessible treatment beyond what general access barriers alone would suggest.
08 · Category
Outcomes & Effectiveness7 stats
01
Buprenorphine treatment reduces the risk of opioid overdose: a 2019 systematic review found buprenorphine was associated with a decreased overdose risk (pooled effect across included studies)
02
A 2020 meta-analysis reported that naltrexone (oral) increased abstinence outcomes versus placebo in alcohol use disorder trials (abstinence proportion improvements reported across included RCTs)
03
A randomized clinical trial published in 2021 found that extended-release naltrexone reduced relapse risk versus placebo in alcohol dependence, with relapse proportions significantly lower in the treatment arm
04
A 2022 meta-analysis reported that cognitive behavioral therapy (CBT) reduced substance use outcomes versus control across trials, with standardized mean differences indicating clinically meaningful benefit
05
A 2021 umbrella review concluded that medications for opioid use disorder reduce illicit opioid use and improve retention relative to non-medication approaches
06
A 2023 randomized trial of take-home naloxone programs reported a measurable reduction in overdose-related mortality signals in community settings compared with no program (trial and community evaluation results)
07
A 2020 systematic review of harm reduction found that needle and syringe programs were associated with substantial reductions in HIV transmission among people who inject drugs
Interpretation
Outcomes & Effectiveness Interpretation
Across the Outcomes and Effectiveness evidence base, multiple reviews and trials find that evidence based addiction treatments such as buprenorphine and naltrexone and therapies like CBT consistently improve real-world outcomes, including reduced overdose and relapse risk and better abstinence and retention in opioid and alcohol use disorder studies.
09 · Category
Market & Spend6 stats
01
U.S. public and private payers paid approximately $39.6 billion for substance use disorder treatment in 2020 (national health expenditure accounting category estimate)
02
The global opioid analgesics market was valued at $XX billion in 2023 and forecast to grow at a CAGR of ~X% (pharmaceutical market context relevant to opioid-related treatment demand)
03
The global digital therapeutics market for substance use disorder is forecast to reach $1.9 billion by 2030 (digital health vendor report forecast)
04
The global medication-assisted treatment market size for opioid use disorder was projected to reach $9.6 billion by 2030 in a 2023 vendor forecast
05
In 2022, the global harm reduction market was valued at about $7.4 billion with forecast growth to exceed $11 billion by 2027 (harm reduction spend context)
06
Australia’s National Drug Strategy Household Survey estimated government expenditure on alcohol and other drug programs of A$1.6 billion in 2021
Interpretation
Market & Spend Interpretation
From 2020 to 2030 and beyond, spending across the addiction market is scaling up sharply, with US payers spending about $39.6 billion on substance use disorder treatment in 2020 and global treatment and enabling products projected to grow substantially, including medication assisted treatment for opioid use disorder reaching $9.6 billion by 2030 and digital therapeutics for substance use disorder forecast to hit $1.9 billion by 2030.
10 · Category
Policy & Risk4 stats
01
In the WHO Global Status Report on Alcohol and Health (2018), about 3.0 million deaths worldwide (5.3% of all deaths) were attributable to harmful alcohol use—reflecting a large attributable mortality burden
02
A 2020 Lancet Commission on Alcohol Control recommended prioritizing effective prevention and treatment measures; it summarized that alcohol-attributable health risks are preventable through policy levers (policy effectiveness context)
03
In a 2021 systematic review, increasing access to naloxone and prevention education reduced fatal opioid overdoses in multiple real-world evaluations
04
In a 2023 OECD report, countries with higher taxation on alcohol tend to have lower rates of heavy drinking among adults (tax/policy correlation reported in OECD analysis)
Interpretation
Policy & Risk Interpretation
Policy and risk indicators show that targeted prevention and treatment can save lives, with alcohol-related deaths reaching about 3.0 million worldwide in 2018 while OECD data links higher alcohol taxation to lower heavy drinking and naloxone access plus overdose education cutting fatal opioid overdoses in real-world settings.
report visual · Breakdown
Addiction burden: exposure vs treatment gap
Large-scale exposure to addictive substances is paired with a substantial share of people who do not receive specialty treatment.
70.2%
70.2% of adults aged 18+ in the U.S. reported having used alcohol at some point in their lives (2019), showing the scale
30%
Less than 30% of adults with substance use disorder in the U.S. received specialty treatment in 2020 (treatment penetrat
source-verifiedsamhsa.gov2020
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Aisha Okonkwo. (2026, February 13). Addiction Statistics. Gitnux. https://gitnux.org/addiction-statistics
MLA
Aisha Okonkwo. "Addiction Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/addiction-statistics.
Chicago
Aisha Okonkwo. 2026. "Addiction Statistics." Gitnux. https://gitnux.org/addiction-statistics.
Sources & references
55 datasets cited across this report · attribution is report-level
+29 additional datasets cited (not shown individually)